Enoxaparin sodium

• Description :

  Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI) .

• Stability :

  ≥ 2 years

• Purity :

  >98% (HPLC)

• Weight :

  1322

• Molecular Formula :

  C42H59N3Na4O35S2

• Notes :

  Research use only, not for human use.

• Receptor :

  Parasite|N-myristoyltransferase-1 (NMT-1)

• CAS Number :

  679809-58-6